



August 5, 2014

## Corium to Report Third Quarter Fiscal Year 2014 Financial Results on Tuesday, August 12, 2014

MENLO PARK, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI) today announced that it will release third quarter fiscal year 2014 financial results on Tuesday, August 12, 2014 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results.

### Conference Call and Webcast Details

Investors and analysts can access the call toll-free by dialing 844-831-3024 (United States) or +1 (315) 625-6887 (international). The conference call will also be available via a live audio webcast on the Investors section of Corium's website at <http://ir.coriumgroup.com/events.cfm>. Please access the website 10 minutes prior to the start of the call to ensure adequate time for any software downloads that may be necessary. A replay of the conference call will be available for two weeks and may be accessed by dialing toll-free 877-670-9780 (United States) or +1 973-409-9247 (international) and entering the conference ID# 83938847 or by visiting Corium's website.

### About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of six prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceuticals and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch currently in Phase 3 trials co-developed with Agile Therapeutics and two additional transdermal products co-developed with Teva. Corium has two proprietary programs in earlier stage clinical development for the treatment of osteoporosis and benign prostatic hyperplasia. For further information, please visit [www.coriumgroup.com](http://www.coriumgroup.com).

CONTACT: Robert S. Breuil

Chief Financial Officer

[bbreuil@coriumintl.com](mailto:bbreuil@coriumintl.com)

Investor and Media Contact:

Karen L. Bergman

BCC Partners

[kbergman@bccpartners.com](mailto:kbergman@bccpartners.com)

(650) 575-1509